Navigation Links
Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
Date:8/12/2009

CRANBURY, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects. Based on the positive results of this study, Palatin has scheduled a meeting with the U.S. Food and Drug Administration to discuss initiation of a Phase 2B study of subcutaneously administered bremelanotide for ED.

"This study supports our hypothesis that increases in blood pressure and gastrointestinal events seen with intranasally administered bremelanotide were primarily related to high plasma levels in a subset of patients. We believe this was due to variability in drug uptake with intranasal administration," said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin. "The switch from intranasal to subcutaneous administration appears to address the blood pressure concerns raised by the FDA. Our next step is to put this data in front of the FDA as we prepare to move bremelanotide back into a Phase 2 study later this year."

Key Results

In all subjects, subcutaneous administration of bremelanotide resulted in consistent and predictable plasma concentrations at levels known from previous studies to improve erectile function. Other key results include:

  • No statistically significant difference in mean changes in blood pressure was seen in subjects receiving bremelanotide compared to placebo.
  • No clinically or statistically significant difference in the range of
    '/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015   Inocucor Technologies Inc ., the ... for farmers, has received a notice of allowance ... its patent application to protect Inocucor consortia and ... enhance yields on farms and in greenhouses. ... IN-M1 microbial consortium and its fermentation byproducts, which ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® ... Monday. The venture will bring the world’s most efficient gas dissolution technology to ... and technologies to both the industrial and municipal markets. With offices located in ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
(Date:7/27/2015)... -- IDEXX Laboratories, Inc. (NASDAQ: IDXX ) announced ... 100,000 specimens to IDEXX Reference Laboratories for symmetric dimethylarginine, ... since the breakthrough kidney function test launched in the ... of suffering and death in cats and dogs. The ... accepted kidney disease prevalence data showing that 1 in ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... 6, 2012 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the 14th ... The live presentation takes place on Monday, February ... Time.  The presentation will be webcast and may be accessed ...
... 6, 2012  BioStorage Technologies, a global provider of ... chain logistics for the bioscience industry, will host ... in Clinical Trials on Tuesday, March 6, 2012 ... The 2-hour workshop will focus ...
... 2012 UV Flu Technologies, Inc. ( OTCBB: ... ahead of schedule in its continuing program to eliminate all debt. ... the remaining and final convertible note, in the amount of $32,500 ... we have made in the last twelve months is nothing short ...
Cached Biology Technology:BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... TORONTO, ON Psychologists at the University of ... interaction has the ability to influence an individual,s sensitivity ... clinical implications for doctor-patient relationships and the general well-being ... of studies over the past several decades have demonstrated ...
... CHICAGO --- Northwestern Medicine researchers at the Robert H. ... a new, nontoxic drug made from a chemical in soy ... to the rest of the body. These findings will ... Research Frontiers in Cancer Prevention Research Conference. Genistein, a ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
Cached Biology News:Psychologists identify influence of social interaction on sensitivity to physical pain 2Soy may stop prostate cancer spread 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2
... The dual-bay DNA Engine Dyad ... for DNA amplification (PCR). The chassis ... units (sample-holder, heat-pump assemblies), which hold ... Color display offers graphical programming with ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
Biology Products: